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Background: Rheumatic heart disease (RHD), the only long term consequence of acute rheumatic fever, remains a
leading cause of morbidity and mortality among young adults in Uganda. An inherited susceptibility to acute
rheumatic fever centers around the major histocompatibility class II human leucocyte antigens. However, there is
paucity of data from sub-Saharan Africa. This study compares the frequency of HLA class II DR alleles between RHD
cases and normal controls in Uganda.
Methods: One hundred ninety-nine participants including 96 established RHD cases aged 5–60 years and 103 age
and sex matched normal controls were recruited for participation. DNA was manually extracted from buffy coat
samples and HLA analysis was performed. HLA-DR allelic frequency comparison between cases and controls were
estimated using conditional logistic regression with 95% confidence intervals. P -values were corrected for multiple
hypothesis testing.
Results: 199 participants (103 female, 51.8%) completed the study. The mean (SD) age in years for cases and
controls were 29.6 (10.2) and 29(18), respectively. After conditional logistic regression and multiple hypothesis
testing, HLA-DR1was associated with a decreased risk of RHD (OR = 0.42, CI 0.21-085, P = 0.01, Corrected P value
(PC) = 0.09,) while HLA-DR11 was associated with increased risk of RHD (OR = 3.31, CI 1.57-6.97, P = <0.001, Pc < 0.001).
No other significant associations were found.
Conclusion: In this first study of HLA genetic susceptibility to RHD in Uganda, HLA- DR1 was more common in normal
controls while HLA- DR11 was more common among RHD cases suggesting a disease susceptibility association. In
future studies, high resolution HLA analysis and genome wide studies should be carried out to confirm this pattern.
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Rheumatic heart disease (RHD) is currently thought to
affect around 70 million people worldwide, with 1.4 million
annual deaths [1]. The vast majority of these cases origin-
ate from central Asia and sub-Saharan Africa [2,3]. In
Uganda, RHD is the most common cause of heart disease
in patients between the ages of 15 and 49 [4].* Correspondence: emmkol@hotmail.com
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unless otherwise stated.Central to the complex pathogenesis of RHD is an
inappropriate immune response triggered by an infection
with rheumatogenic strains of Group A beta-haemolytic
streptococcus. However, only 3-6% of those infected de-
velop acute rheumatic fever [5], and genetic host suscep-
tibility factors are thought to play a key role in disease
development [6,7].
While there are many remaining questions, host sus-
ceptibility appears to center around the major histocom-
patibility complex (MHC) human leukocyte antigens
(HLA) and other cellular antigen variants [8,9]. The
MHC is a critical component of antigen presentation.
Variations between HLA antigens can affect T-cell responseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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cytokines that play a role in the initial and ongoing cardiac
damage seen in RHD. A number of MHC class II alleles
including HLA-DR, DQ and DB loci have been implicated
in this process [10,11]; however, a great deal of variability
between patients from different ethnic backgrounds exists
[11,12]. In Uganda, as in much of sub-Saharan Africa, there
is a lack of data on genetic susceptibility to RHD. This is the
first study to analyze HLA in RHD patients in Uganda and
Eastern sub-Saharan Africa, and to our knowledge, the
largest HLA study conducted.
Methods
Ethical approval
Ethical approval for the study was provided by the Institu-
tional Review Board of the School of Medicine, Makerere
University College of Heath Sciences and permission con-
firmed through the Uganda National Council for Science
and Technology (UNCST).
The study conformed to the principles outlined in the
declaration of Helsinki. Each study participant aged
18 years and above gave a written informed consent.
Parents or next of kin gave written informed consent on
behalf of the minor participants.
Study design
A matched case control study was conducted comparing
the frequency of MHC class II HLA- DR alleles between
patients with established RHD and normal controls in a
population of ethnic black Ugandans.
A total of 199 participants took part in the study.
Ninety six established RHD cases, aged 5 to 60 years
were recruited from the general cardiac outpatient clinic,
pediatric cardiac clinic, and the general inpatient cardi-
ology ward at the Uganda Heart Institute (UHI), Mulago
Hospital Complex. All study participants underwent
echocardiography and met criteria for definite RHD
based on the 2012 World Heart Federation (WHF) guide-
lines for echocardiographic diagnosis of RHD [13]. One
hundred and three controls were recruited from healthy
relatives of patients being seen at the hospital for reasons
other than RHD, and were age matched within five years
of cases. All control subjects also underwent echocardiog-
raphy to confirm that they did not have RHD. Other ex-
clusion criteria included history or evidence of connective
tissue disease, any abnormality noted on echocardiogram,
and unwillingness to sign informed consent/assent.
For our power calculation, we used an anticipated
difference of 10% between HLA frequency between cases
and controls. In order to achieve an 80% chance of
detecting an association between HLA and RHD (type I
error rate of 5%), 88 cases and 88 controls would need
to be recruited. The estimated sample size was increased
to 100 per group to account for any losses.Study procedure
Following a written informed consent/assent, each study
participant underwent a clinical examination followed by
echocardiography according to the European society of
cardiology guidelines [14].
Sample preparation and DNA extraction
Six (6) milliliters of venous blood were obtained from each
participant. Samples were centrifuged and buffy coat sepa-
rated and stored at −80 degrees Celsius. During DNA ex-
traction, the frozen sample was thawed and DNA extraction
was preformed manually using the Genotype DNA isolation
kit (Hain lifesciences, Nehren, Germany). DNA extraction
and HLA analysis was conducted at the MBN DNA Labora-
tory, Kampala, Uganda.
HLA-DR DNA polymerase chain reaction (PCR)
DNA typing for HLA-DR was performed through poly-
merase chain reaction (PCR) amplification (GeneAmp
PCR System 9700, Applied Biosystems, California, USA)
with Olerrup sequence specific primers (low resolution
Olerup SSP® HLA Typing Kits, Stockholm, Sweden) ac-
cording to protocol, as previously described [15]. The
final amplicons were stored at 4 degrees Celsius until
electrophoresis was performed.
Sequence-specific primers (PCR-SSP) distinguish spe-
cific alleles or groups of alleles by sequence differences
at the 3' end of the primer [16]. After PCR amplification,
the amplified DNA fragments were size-separated in
2.0% Agarose gel (PEQLAB Biotechnologies, Germany)
stained with ethidium bromide and then visualized
under UV light. The 100 bp DNA ladder (Solis BioDyne,
Estonia) was used as the size marker.
Statistical analysis
Statistical analysis
Allelic frequencies of HLA-DR from study participants
were evaluated in STATA (Version 13, College Station,
TX: Stata Corporation). The significance of the differ-
ences of between HLA-DR alleles was determined using
Chi square analysis. Fisher’s exact test was used for small
expected frequencies. P-values were considered statisti-
cally significant if its value was < 0.05. Conditional logis-
tic regression analysis was conducted to determine odds
ratios of the strength of association between HLA-DR
alleles and RHD. P-values were further adjusted for mul-
tiple hypothesis testing by multiplying the P-values by
the group number (9). Data was managed with Epi Data
3.0 (Odensk, Denmark) [17].
Results
Demographic information for the 199 participants (96
cases and 103 controls) can be found in Table 1. Match-
ing was successful with the ratio of male to female
Table 1 Baseline characteristics
Variable Total Cases Controls P value
Age
Mean (SD) 29.4(12.1) 29.6(10.2) 29.8(9.8) 0.88
Sex
Male (N,%) 96(46.7%) 50(52%) 51(49.5%) 0.72
SD- Standard deviation.
Table 3 Conditional regression analysis of association
between HLA DR alleles and RHD
Variable OR (95% CI) P value Pc
HLA DR1 0.42(0.21-0.85) 0.01 0.09
HLA DR3 0.65 (0.24-1.76) 0.4
HLA DR7 2.5 (0.83-7.5) 0.1
HLA DR8 0.54 (0.15-1.93) 0.34
HLA DR9 2.08(0.42-10.3) 0.36
HLA DR10 3.42 (0.68-17.27) 0.13
HLA DR11 3.31(1.57-6.97) 0.0007 <0.006
HLA DR13 0.63(0.17-2.21) 0.47
HLA DR17 0.62(0.26-1.47) 0.28
Pc- Corrected P value for multiple hypothesis testing.
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in years for cases and controls were 29.6 (10.2) and 29
(18), respectively.
Table 2 displays the results of HLA-DR allelic frequen-
cies between the two groups. There was a lower fre-
quency of HLA-DR1 in cases compared to controls,
(14.6% versus 31.3%), and a higher frequency of HLA-
DR11 in cases compared to controls (31.3% versus 10.7%).
After conditional regression analysis and adjusting for
multiple hypothesis testing, HLA-DR1 (OR = 0.42, CI
0.21-0.85, P = 0.01, Corrected P value (Pc) =0.09) was
demonstrated to be associated with a decreased risk of
RHD while HLA-DR11 (OR = 3.31, CI 1.97- 6.97, P <
0.0007, Pc = 0.006) was significantly associated with
RHD (Table 3).
Discussion
This is the first study of genetic susceptibility to RHD in
Uganda. The results suggest that different class II MHC
genes may result in both increased susceptibility to and
increased protection from RHD. We found a significant
association of HLA-DR11 in patients affected by RHD
and a decreased risk of RHD in association with HLA-
DR1.
In other populations, HLA-DR1 has been implicated as
being both a protective factor and a susceptibility factor.
Gundogdu et al., found a significantly higher frequency of
HLA-DRB1*01 in controls compared to RHD patients
[18]. However, Maharaj et al., found that patients withTable 2 HLA DR allelic frequencies between RHD cases
and non RHD controls
Variable Total (n,%) Cases (n,%) Controls (n,%) P value
HLA DR1 45/199, 22.6% 14/96, 14.6% 31/103, 30.1% 0.01
DR3 18/199,9.04% 7/96, 7.29% 11/103, 10.7% 0.4
DR7 16/199, 8.04% 11/96, 11.5% 5/103, 4.9% 0.1
DR8 11/199, 5.53% 4/96, 4.2% 7/103, 6.8% 0.34
DR9 7/199, 3.52% 4/96, 4.2% 3/103, 2.9% 0.36
DR10 8/199, 4.02% 6/96, 6.3% 2/103, 1.9% 0.13
DR11 41/199,20.60% 30/96, 31.3% 11/103, 10.7% <0.001
DR13 11/199, 5.53% 4/96, 4.2% 7/103, 6.8% 0.47
DR17 24/199,12.06% 9/96, 9.4% 15/103, 14.6% 0.28
HLA- Human leukocyte antigen.RHD had a higher frequency of HLA-DR1 compared to
healthy controls [19]. Mixed results have also been re-
ported for the HLA-DRB1*11 allele. Chou et al., showed
an increase in HLA-DRB1*11 in RHD patients in Taiwan
[7] but Haydardedeoglu et al. [20], and Guadalupe et al.,
[9], found HLA-DRB1*11 to be decreased in RHD patients
from Turkey and Mexico, respectively. These differences
in RHD associations across different populations support
the concept of ethnic specific genetic susceptibility for
HLA alleles [5]. Other explanations for the variability of
studies include small sample sizes which may not capture
rare HLA alleles, different typing methods (serologic ver-
sus DNA based), and heterogeneity of the causative agent.
More than fifteen streptococcal strains have been associ-
ated with rheumatic fever and each distinct strain may
select for a unique DR antigen, resulting in different
susceptibility alleles [11].
Africa has one of the most genetically diverse popula-
tions [21], thus differences in HLA alleles is expected
between various geographic locations in sub-Saharan
Africa. In a study that examined HLA susceptibility in
black South Africans, Maharaj et al., found an increase
in HLA-DR6 in patients with RHD and no significant
change in HLA-DR2 [19], while these alleles were ab-
sent in both cases and controls of our study. Carlquist
et al., in a meta-analysis of HLA-DR association with
RHD, showed that DR 1 was the susceptibility gene in
blacks (South Africans and African Americans) and DR 3
and DR4 was the susceptibility genes in East Indians and
American whites, respectively [11]. In our study, DR1 was
not associated with RHD while DR3 was only marginally
present (7 cases and 11 controls), and DR4 was absent.
A potential weakness of many HLA association stud-
ies, including ours, is a low level HLA typing which does
not account for the multitude of polymorphisms found
in the MHC [19]. Despite this weakness, ours is the only
HLA study in RHD to have been conducted in Uganda
[22] and the largest one [19,23,24].
Okello et al. BMC Cardiovascular Disorders 2014, 14:28 Page 4 of 5
http://www.biomedcentral.com/1471-2261/14/28A strength of this study is the homogeneity of the
cases and controls as ethnic diversity and population
stratification can weaken the association of HLA to
RHD and cause spurious allelic associations [25]. The
Ugandan population is mostly all black African with a
small minority of Indians. In the present study all study
participants were ethnic blacks.
More work needs to be done in genetic susceptibility
to RHD and many questions remain unanswered. The
HLA system is likely not the only important part of
genetic susceptibility, and an unbiased search of the
genome with a genome wide association study is war-
ranted to give the full spectrum of genetic susceptibil-
ity to RHD.
Conclusion
In this first study of the association between the MHC
class II HLA-DR antigens and RHD in Uganda, we have
found that HLA-DR1 was more common in healthy con-
trols while HLA DR11 was more common among RHD
cases suggesting a disease susceptibility association. Fur-
ther studies, including high resolution HLA analysis and
whole genome interrogations should be carried out to
confirm this pattern.
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